We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RXRX market cap is 1.74B. The company's latest EPS is USD -1.1445 and P/E is -5.27.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 10.53M | 10.89M | 13.79M | 14.42M | 26.08M |
| Operating Income | -99.55M | -98.93M | -96.34M | -100.54M | -98.35M |
| Net Income | -93.02M | -93M | -91.37M | -97.54M | -95.84M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.32M | 3.96M | 10.18M | 39.84M | 44.58M |
| Operating Income | -62.44M | -84.38M | -182.78M | -245.73M | -350.06M |
| Net Income | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 630.83M | 653.7M | 557.85M | 775.86M | 726.5M |
| Total Liabilities | 192.86M | 190.26M | 156.7M | 191.41M | 201.94M |
| Total Equity | 437.97M | 463.44M | 401.15M | 584.45M | 524.56M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 101.43M | 298.59M | 610.35M | 701.29M | 653.7M |
| Total Liabilities | 24.59M | 56.56M | 67.41M | 215.48M | 190.26M |
| Total Equity | -124.27M | -206.29M | 542.94M | 485.81M | 463.44M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -213.7M | -287.78M | -102.3M | -184.52M | -243.74M |
| Investing | -7.74M | -10.23M | -6.65M | -10.84M | -15.4M |
| Financing | 59.47M | 140.13M | 13.9M | 277.02M | 293.48M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -57.04M | -45.4M | -158.61M | -83.52M | -287.78M |
| Investing | -3.91M | -8.74M | -271.74M | 193.25M | -10.23M |
| Financing | 120.41M | 246.14M | 458.54M | 154.35M | 140.13M |
| Market Cap | 1.74B |
| Price to Earnings Ratio | -5.27 |
| Price to Sales Ratio | 38.78 |
| Price to Cash Ratio | 4.41 |
| Price to Book Ratio | 3.73 |
| Dividend Yield | - |
| Shares Outstanding | 286.64M |
| Average Volume (1 week) | 15.96M |
| Average Volume (1 Month) | 16.14M |
| 52 Week Change | -39.28% |
| 52 Week High | 15.74 |
| 52 Week Low | 5.60 |
| Spread (Intraday) | 1.22 (16.94%) |
| Company Name | Recursion Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.recursion.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
